The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)

CA119170

7947 (ClinVar)

Gene: MYOC
Condition: juvenile open angle glaucoma
Inheritance Mode: Autosomal dominant inheritance
UUID: 30a3432f-835c-4e0b-942a-7a84d0c5f07c

HGVS expressions

NM_000261.2:c.1091G>T
NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)
NC_000001.11:g.171636349C>A
CM000663.2:g.171636349C>A
NC_000001.10:g.171605489C>A
CM000663.1:g.171605489C>A
NC_000001.9:g.169872112C>A
NG_008859.1:g.21285G>T
ENST00000037502.11:c.1091G>T
ENST00000637303.1:c.235-2281C>A
ENST00000638471.1:c.*429G>T
ENST00000037502.10:c.1091G>T
ENST00000614688.1:c.*55G>T
NM_000261.1:c.1091G>T

Likely Pathogenic

Met criteria codes 5
PS4_Supporting PM2_Supporting PS3_Moderate PP3 PP1_Strong
Not Met criteria codes 10
BS3 BS1 BP7 BP4 PS2 PS1 PM6 BA1 PM5 PM4

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Glaucoma Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Glaucoma VCEP
The c.1091G>T variant in MYOC is a missense variant predicted to cause substitution of Glycine by Valine at amino acid 364 (p.Gly364Val). This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles. The REVEL score = 0.896, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function. A previous study (PMID: 16466712) demonstrated that the Gly364Val protein had reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function. 18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family). 2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands). In summary, this variant met the criteria to receive a score of 9 and to be classified as likely pathogenic (likely pathogenic classification range 6 to 9) for juvenile open angle glaucoma based on the ACMG/AMP criteria met, as specified by the ClinGen Glaucoma VCEP (v1, 12 Oct 2021): PP1_Strong, PS3_Moderate, PP3, PS4_Supporting, PM2_Supporting
Met criteria codes
PS4_Supporting
2 probands with JOAG or POAG have been reported carrying this variant (PMID: 10196380), which met PS4_Supporting (≥ 2 probands).
PM2_Supporting
This variant was not found in any population of gnomAD (v2.1.1), meeting the ≤ 0.0001 threshold set for PM2_Supporting in a population of at least 10,000 alleles.
PS3_Moderate
A previous study (PMID: 16466712) demonstrated that the Gly364Val protein had reduced secretion levels compared to wild type myocilin protein and met the OddsPath threshold for PS3_Moderate (> 4.3), indicating that this variant did impact protein function.

PP3
The REVEL score = 0.896, which met the ≥ 0.7 threshold for PP3, predicting a damaging effect on MYOC function.
PP1_Strong
18 segregations in 2 families, with juvenile or primary open angle glaucoma (JOAG or POAG), have been reported (PMID: 9535666), which fulfilled PP1_Strong (≥7 meioses in >1 family).
Not Met criteria codes
BS3
This criterion was not met as PS3_Moderate has been met.
BS1
This criterion was not met as PM2_Supporting has been met.
BP7
This is not a synonymous or non-coding variant.
BP4
This criterion was not met as PP3 has been met.
PS2
This variant has not been identified de novo.
PS1
An established pathogenic variant causing this same amino acid change has not been identified.
PM6
This variant has not been identified de novo.
BA1
This criterion was not met as PM2_Supporting has been met.
PM5
No other missense variants at this amino acid residue have been identified.
PM4
This variant does not cause a protein length change.
Approved on: 2022-02-21
Published on: 2022-07-11
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.